Cargando…

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis

High-grade serous ovarian cancer (HGSOC) is a lethal malignancy characterized by an immunosuppressive tumor microenvironment containing few tumor infiltrating lymphocytes (TILs) and an insensitivity to checkpoint inhibitor immunotherapies. Gains in the PTK2 gene encoding focal adhesion kinase (FAK)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozmadenci, Duygu, Shankara Narayanan, Jayanth S., Andrew, Jacob, Ojalill, Marjaana, Barrie, Allison M., Jiang, Shulin, Iyer, Samhita, Chen, Xiao Lei, Rose, Michael, Estrada, Valeria, Molinolo, Alfredo, Bertotto, Thomas, Mikulski, Zbigniew, McHale, Michael C., White, Rebekah R., Connolly, Denise C., Pachter, Jonathan A., Kuchroo, Vijay K., Stupack, Dwayne G., Schlaepfer, David D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169934/ https://www.ncbi.nlm.nih.gov/pubmed/35467979 http://dx.doi.org/10.1073/pnas.2117065119

Ejemplares similares

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
por: Diaz Osterman, Carlos J, et al.
Publicado: (2019)

Prognostic value of CD155/TIGIT expression in patients with colorectal cancer
por: Murakami, Daisuke, et al.
Publicado: (2022)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway
por: Ma, Bin, et al.
Publicado: (2019)

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
por: Wang, Daijun, et al.
Publicado: (2022)

Mechanisms of TIGIT-driven immune suppression in cancer
por: Kurtulus, Sema, et al.
Publicado: (2014)

Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma
por: Duan, Xiangguo, et al.
Publicado: (2019)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
por: Matsuo, Tomohei, et al.
Publicado: (2022)

The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

Blocking TIGIT/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer
por: Liu, Lu, et al.
Publicado: (2022)

Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy
por: Ducoin, Kathleen, et al.
Publicado: (2022)

Examination of the TIGIT-CD226-CD112-CD155 Immune Checkpoint Network during a Healthy Pregnancy
por: Meggyes, Matyas, et al.
Publicado: (2022)

Cortactin as a Target for FAK in the Regulation of Focal Adhesion Dynamics
por: Tomar, Alok, et al.
Publicado: (2012)

Integrin α2β1 decelerates proliferation, but promotes survival and invasion of prostate cancer cells
por: Ojalill, Marjaana, et al.
Publicado: (2018)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

FAK promotes recruitment of talin to nascent adhesions to control cell motility
por: Lawson, Christine, et al.
Publicado: (2012)

FAK promotes recruitment of talin to nascent adhesions to control cell motility
por: Lawson, Christine, et al.
Publicado: (2012)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Differential regulation of cell motility and invasion by FAK
por: Hsia, Datsun A., et al.
Publicado: (2003)

Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia
por: Szereday, Laszlo, et al.
Publicado: (2021)

EGFR-dependent pancreatic carcinoma cell metastasis via Rap1 activation
por: Huang, Miller, et al.
Publicado: (2011)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy
por: Ring, Jennifer, et al.
Publicado: (2015)

FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth
por: Tancioni, Isabelle, et al.
Publicado: (2015)

Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling
por: Eliceiri, Brian P., et al.
Publicado: (2002)

CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell–induced natural killer–cell exhaustion in multiple myeloma
por: Liu, Zhao‐Yun, et al.
Publicado: (2022)

Myosin II activity regulates vinculin recruitment to focal adhesions through FAK-mediated paxillin phosphorylation
por: Pasapera, Ana M., et al.
Publicado: (2010)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

TIGIT in Lung Cancer: Potential Theranostic Implications
por: Pescia, Carlo, et al.
Publicado: (2023)

Whole Genome Pathway Analysis Identifies an Association of Cadmium Response Gene Loss with Copy Number Variation in Mutant p53 Bearing Uterine Endometrial Carcinomas
por: Delaney, Joe Ryan, et al.
Publicado: (2016)

FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β
por: Gao, Chenxi, et al.
Publicado: (2015)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

Inhibition of FAK kinase activity preferentially targets cancer stem cells
por: Kolev, Vihren N., et al.
Publicado: (2017)

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer
por: Blessin, Niclas C., et al.
Publicado: (2019)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

TIGIT limits immune pathology during viral infections
por: Schorer, Michelle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ccks1i5v9e6ht6jjapklmfkdvr